These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18455853)

  • 1. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis.
    Shan HY; Rana S; Epstein FH; Stillman IE; Karumanchi SA; Williams ME
    Am J Kidney Dis; 2008 Jun; 51(6):1029-32. PubMed ID: 18455853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia.
    Sandrim VC; Palei AC; Metzger IF; Gomes VA; Cavalli RC; Tanus-Santos JE
    Hypertension; 2008 Aug; 52(2):402-7. PubMed ID: 18574068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy.
    Salahuddin S; Lee Y; Vadnais M; Sachs BP; Karumanchi SA; Lim KH
    Am J Obstet Gynecol; 2007 Jul; 197(1):28.e1-6. PubMed ID: 17618745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers.
    Metz TD; Allshouse AA; Euser AG; Heyborne KD
    Am J Obstet Gynecol; 2014 Nov; 211(5):512.e1-6. PubMed ID: 24769011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia.
    Staff AC; Braekke K; Johnsen GM; Karumanchi SA; Harsem NK
    Am J Obstet Gynecol; 2007 Aug; 197(2):176.e1-6. PubMed ID: 17689641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic biomarkers in pregnancy: defining maternal and fetal health.
    Rasmussen LG; Lykke JA; Staff AC
    Acta Obstet Gynecol Scand; 2015 Aug; 94(8):820-32. PubMed ID: 25753566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of antiangiogenic factors in preeclamptic pregnancies.
    Zhao W; Qiao J; Zhang Q; Zhao Y; Chen Q
    Growth Factors; 2010 Aug; 28(4):293-8. PubMed ID: 20214506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
    Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
    Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia.
    Dwyer BK; Krieg S; Balise R; Carroll IR; Chueh J; Nayak N; Druzin M
    J Matern Fetal Neonatal Med; 2010 Jul; 23(7):705-11. PubMed ID: 19895348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging new biomarkers of preeclampsia.
    Polsani S; Phipps E; Jim B
    Adv Chronic Kidney Dis; 2013 May; 20(3):271-9. PubMed ID: 23928393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations among antiangiogenic factors and trace elements in hypertensive disorders of pregnancy.
    Rezende VB; Barbosa F; Palei AC; Cavalli RC; Tanus-Santos JE; Sandrim VC
    J Trace Elem Med Biol; 2015 Jan; 29():130-5. PubMed ID: 25053574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenic factors and preeclampsia.
    Tjoa ML; Levine RJ; Karumanchi SA
    Front Biosci; 2007 Jan; 12():2395-402. PubMed ID: 17127249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can serum HCG values be used in the differential diagnosis of pregnancy complicated by hypertension?
    Gurbuz A; Karateke A; Mengulluoglu M; Gedikbasi A; Ozturkmen M; Kabaca C; Sahinoglu Z
    Hypertens Pregnancy; 2004; 23(1):1-12. PubMed ID: 15117595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis.
    de Jesus GR; de Jesus NR; Levy RA; Klumb EM
    Lupus; 2014 Oct; 23(12):1299-301. PubMed ID: 25228732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
    Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
    Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
    Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining and predicting preeclampsia.
    Lindheimer MD; Umans JG
    N Engl J Med; 2006 Sep; 355(10):1056-8. PubMed ID: 16957153
    [No Abstract]   [Full Text] [Related]  

  • 20. Obstetric nephrology: preeclampsia--the nephrologist's perspective.
    Umans JG
    Clin J Am Soc Nephrol; 2012 Dec; 7(12):2107-13. PubMed ID: 23065496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.